Clinical Trial Update: A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke [Phase 1, Phase 2]

View source ↗

Summary

Astellas is conducting Phase 1/2 trials of ASP2246 for movement problems caused by brain injury after chronic ischemic stroke; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• ASP2246

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Chronic Ischemic Stroke | Phase 1, Phase 2 | Status: RECRUITING